Introduction
Although gallbladder cancer (GBC) is relatively rare in Western populations, it is the most common biliary tract malignancy. Its overall 5-year survival rate is less than 5%, but the prognosis is very dependent of the disease stage [
1]. Symptoms are often non-specific and do not occur until late in the disease course. Patients are frequently diagnosed at a stage in which extended resection is necessary to achieve a radical resection.
Up to 70% of patients with GBC is diagnosed incidentally (iGBC), during or after cholecystectomy for a presumed benign indication, such as cholecystolithiasis or cholecystitis [
2,
3]. Due to the risk of residual disease, re-resection is recommended in patients with pathologically confirmed stages T1b, T2, and T3 disease to improve survival [
4]. The remaining 30% are diagnosed primarily with GBC (pGBC), mainly through radiological imaging.
In patients with disseminated disease (DD, defined as either locally unresectable or metastatic disease), resection does not improve survival [
5]. To detect DD and improve selection of patients for surgery, imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) are used [
6]. Unfortunately, the sensitivity of imaging for DD in GBC patients is low, with reported sensitivities between 70 and 80% [
7,
8]. Therefore, DD is frequently detected during exploratory laparotomy [
9].
Routine staging laparoscopy (SL) may avoid an unnecessary laparotomy. Although some studies report on the use of SL in GBC, the majority of previous studies stem from single-centre series, and generalizability may be limited [
10‐
14]. Moreover, only one study investigated the value of SL and potential predictive factors for DD in iGBC [
12].
This study aims to assess the value of SL for both pGBC and iGBC to define its role in the current treatment strategy for GBC patients. In addition, this study aims to identify predictors for DD in iGBC patients.
Discussion
This study assessed the yield of SL before laparotomy in patients with pGBC and patients with iGBC. Of 183 patients with pGBC planned for resection, 143 (78%) did not undergo SL, 42 of which (29%) showed DD at laparotomy. Of 40 pGBC patients where SL was performed before planned resection, DD was found in eight.
Of 107 included iGBC patients, 100 (93%) did not undergo SL before planned re-resection, 19 of which (19%) showed DD at laparotomy. DD was found in one of seven iGBC patients that underwent SL before re-resection. This study identified cholecystitis and R1/R2 resection at primary cholecystectomy as independent predictive factors of DD in iGBC patients.
Regarding the use of SL in pGBC, results of previous publications are diffuse. The yield of SL in pGBC reported was generally higher than the present study and ranged from 23 to 62% [
9‐
11,
13,
14]. A study from India including 409 pGBC patients undergoing SL reported a yield of 23.2%, which accords with our findings [
10].
Studies assessing the yield of SL before re-resection in patients with iGBC are scarce. As iGBC is often diagnosed at an earlier stage, a lower yield for SL in comparison with pGBC is expected. A series of 136 iGBC patients treated in the Memorial Sloan-Kettering Cancer Center [
12] found a yield of SL of only 4.3%. The authors reported that a higher T stage, positive resection margin, and poor tumour differentiation were found to be independent predictors of DD. In a prior paper from the same group, SL demonstrated DD in 2 out of 10 iGBC patients [
14].
It must be noted that nine of 32 pGBC patients deemed potentially resectable during SL showed DD at laparotomy. This can be partially explained due to the difficulty of estimating resectability of locally advanced disease in SL, which was the reason for unresectability in four of the nine. No correlation between delayed timing of laparotomy after SL and the presence of DD at laparotomy was found in this study. In pGBC, the resection rate did not differ between patients with and without SL (72% vs.71%; p = 0.89). However, patients who did receive SL had signs of advanced disease (i.e. liver invasion) on preoperative imaging more frequently. Since SL is generally conducted in higher-stage patients, this may result in selection bias and explain the equal resectability rates.
In iGBC patients, yield of SL was lower; peritoneal metastases were detected by SL in one of seven patients. SL missed DD in two patients due to lymph node metastases. DD was most often present in patients with R1/R2 resection or cholecystitis. Possibly, the relation of cholecystitis with DD stems from its higher chance of bile spill during initial cholecystectomy, which has been described as a risk factor for DD [
19].
Although previous studies comment on the usefulness of FDG PET-CT in the workup of patients with GBC, guidelines in the Netherlands only recommend its use when doubt regarding the presence of distant metastases exists on regular CT [
20]. Also, there have been significant improvements in imaging technology during the inclusion period. These factors might have a positive effect on current radiological examination of disseminated disease and might therefore introduce bias and affect the yield of staging laparoscopy.
Based on the outcome of this study, we recommend SL for every patient with suspected pGBC in whom resection is considered as its yield is significant and the time investment is limited. Since the value of SL in iGBC seems moderate, SL should be considered in patients with high risk of DD (i.e. patients with cholecystitis or initial R1/R2 resection).
Due to the low incidence of GBC, international collaboration is of vital importance to obtain data on a larger cohort of patients. Currently, a large international study on the operative management of early gallbladder cancer, the OMEGA study, is being set up to further improve our knowledge on the treatment of gallbladder cancer.
Strengths of the present study include the nationwide design, which may provide outcomes which more accurately reflect the overall population compared to results from studies that only include data from high volume expert centres. Moreover, it is the first paper to research this topic in a European population and examines the use of SL in both pGBC and iGBC patients. There are some limitations to the current study. Primarily, the interpretation of results of a retrospective cohort study is vulnerable to selection bias, in this case primarily due to the higher likeliness of patients with more advanced disease to undergo SL. Secondarily, selection algorithms for SL were not available and likely varied greatly per institution, which could skew results as well as introduce a considerable amount of selection bias when the surgeon decides on which patients apply for SL. In addition, details on periprocedural aspects of SL were not described in detail for each patient. Therefore, the thoroughness of SL and whether or not liver ultrasonography was performed could not be verified. Furthermore, the median time between primary surgery and re-resection in iGBC patients was 75 days, whereas 4 to 8 weeks have been suggested in literature as the optimal time interval to re-resection [
21]. Thus, the chance of recurrence was higher in a part of the iGBC group due to this delay. Finally, for some patients, the exact location of DD was not clearly reported. For example, no differentiation was made between surface or deep parenchymal liver metastasis, and it was therefore impossible to record whether SL could have detected the metastasis.
In conclusion, SL before planned resection for pGBC obviates a nontherapeutic laparotomy in one in five patients. In iGBC patients, SL has a lower yield but is indicated after primary resection for cholecystitis and after initial R1/R2 resection due to their highest risk of DD.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.